A practical reference on reverse-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
Reconstitution concentration is chosen from the mass of peptide and the volume of solvent added. Researchers often prepare a concentrated stock and then divide it into single-use aliquots to reduce freeze-thaw cycling. The actual peptide content may differ from label mass because of counterions, water, or impurities. For that reason, quantitative work may require independent measurement such as amino acid analysis or ultraviolet absorbance. Records of solvent, volume, date, and lot help trace later observations.
Lyophilized peptides are supplied as dry powders or porous cakes that remain stable during shipment and short-term storage. Reconstitution is the laboratory step of adding a suitable solvent so the solid dissolves into a liquid stock. The dried state limits hydrolysis and microbial growth, but it does not remove all residual water or salts. Sequence, counterion, and manufacturing method influence how quickly and completely a peptide enters solution. Researchers treat reconstitution as a practical starting point for later dilution, analysis, or assay work.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
Quality verification after reconstitution may include visual inspection, pH measurement, and chromatographic analysis. Reverse-phase high-performance liquid chromatography can reveal degradation peaks, while mass spectrometry can confirm molecular identity. Concentration may be estimated from the weighed peptide mass or determined by amino acid analysis, UV absorbance, or quantitative chromatography. Documentation of solvent, volume, date, and storage conditions supports traceability and reproducibility. Records also help identify when a solution was prepared and whether it has exceeded an established in-house shelf life.
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
| Property | Value | Notes |
|---|---|---|
| Appearance (lyophilized) | White to off-white powder or cake | Depends on peptide sequence, counterion, and manufacturing process |
| Appearance (reconstituted) | Clear to slightly hazy solution | Visible particles may indicate incomplete dissolution or aggregation |
| Solubility class | Aqueous or organic-dependent | Hydrophilic peptides often dissolve in water; hydrophobic peptides may require acetonitrile or dimethyl sulfoxide |
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccated, protected from light, and allowed to equilibrate before opening |
| Typical analytical method | Reverse-phase HPLC or LC-MS | Used to confirm identity, purity, and concentration after dissolution |
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
Analytical checks help determine whether a reconstituted peptide matches its expected identity and purity; reverse-phase high-performance liquid chromatography separates components by hydrophobicity and can reveal degradation products or impurities. Mass spectrometry provides a mass measurement that supports sequence identity when compared with the theoretical value. Ultraviolet absorbance at 280 nm can estimate concentration for peptides containing tryptophan or tyrosine, though sequence-dependent extinction coefficients are needed. For shorter or non-aromatic peptides, other methods such as amino acid analysis may be required. These techniques describe the material rather than guarantee its biological effect.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
Quality control for reconstituted peptides includes recording lot number, solvent, date, and storage conditions. Visual inspection checks clarity, color, and particles, while pH measurement verifies the expected solution environment. Concentration is often estimated by ultraviolet absorbance at 280 nm for peptides containing tryptophan or tyrosine, or by high-performance liquid chromatography. Mass spectrometry can confirm molecular identity before reconstitution. Sterility testing is relevant when microbial contamination would invalidate an experiment, though such testing is not routinely performed in every laboratory.
The choice of solvent is guided by peptide properties and the intended downstream use. Water alone can dissolve many hydrophilic peptides, while hydrophobic sequences may require a small amount of an organic solvent or a buffered solution. Some peptides carry net charges that affect solubility across pH values. The pH of the final solution can influence stability and aggregation. In research settings, the solvent is selected to match the assay or analytical method rather than for any therapeutic purpose.
During reconstitution, liquid is directed toward the wall of the vial rather than forcefully onto the powder. Gentle swirling or inversion mixes the contents without creating excessive foam or shear. Foaming can denature some peptides and can make volume measurement difficult. Complete dissolution is often confirmed by visual inspection against a light source. Particles, cloudiness, or undissolved material may indicate incomplete mixing, aggregation, or a solubility limitation that requires further investigation.
1953 - Li was the first to isolate and extract ACTH. 1964 - Li and his research team discovered and isolated lipotropin, and its structure was defined in 1965. 1975 - Li discovered β-endorphin when trying to find β-lipotropin in camel brain. The team isolated human β-endorphin in 1976 and synthesized it to study its biological activity after they defined the structure of β-endorphin. The second group includes follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH).
== Background == The Government of India and UNESCO signed a Memorandum of Understanding (MoU) on 14 July 2006 to establish RCB. The centre is now recognized as a "Category II Centre" by "the principles and guidelines for the establishment and functioning of UNESCO Institutes and Centres". Following approval from the Union Cabinet, the centre became operational from its interim campus at Gurgaon, Haryana from 20 April 2009.
Zverev then lost in the first round of Wimbledon to Arthur Rinderknech in five sets, which marked the first time he lost in the first round of a major since 2019. Zverev reached the semifinals for the first time in Canada since winning the title in 2017 after defeating the defending champion Alexei Popyrin in the quarterfinals. He lost to the eventual finalist Karen Khachanov, despite holding a match point. He rebounded in Cincinnati by advancing to his 3rd consecutive semifinal in the American Midwest, which included wins against the recent finalists from Toronto the week before, Khachanov and Ben Shelton, both of whom were notably exhausted from their Canadian campaigns. Zverev, also struggling and exhausted in his semifinal against Carlos Alcaraz, went on to lose in straight sets. In New York, he was defeated in four sets by a resurgent Félix Auger-Aliassime. Before leaving the United States, Zverev participated in the Laver Cup with Team Europe in San Francisco but lost to Team World. In the Asian swing, Zverev was defeated by frequent rival Daniil Medvedev in the quarterfinals in Beijing, and by eventual finalist Arthur Rinderknech in the third round in Shanghai. Zverev returned to form in the European indoor swing, but found himself obstructed by Jannik Sinner for the remainder of the season, losing to him in the final in Vienna, the semifinals of Nanterre, and a round-robin match in Turin. At the Davis Cup Finals, Zverev won both of his singles matches, but Germany was defeated in the semifinal tie against Spain. He ended his season ranked world No.
This change from an irregular cavalry force that fought against the enemies of Russia, such as the Ottoman Empire and France, to a repressive gendarmerie deployed against the subjects of the Empire caused much disquiet within the various Hosts, as it was contrary to the heroic ethos of frontier warfare that the Cossacks cherished. In 1879, the Shah of Iran, Nasir al-Din, who had been impressed with the equestrian skills and distinctive uniforms of the Cossacks while on a visit to Russia the previous year, requested that the Emperor Alexander II sent some Cossacks to train a Cossack force for himself. Alexander granted his request and later in 1879 a group of 9 Cossacks led by Kuban Cossack Colonel Aleksey Domantovich arrived in Tehran to train the Persian Cossack Brigade. The shah very much liked the colorful uniforms of the Cossacks and Domantovich devised uniforms for one regiment of the brigade based on the uniforms of the Kuban Cossack Host and another regiment had its uniform based on the Terek Cossack Host. The uniforms of the Cossacks were based on the flamboyant costumes of the peoples of the Caucasus, and what in Russia were viewed as exotic and colorful uniforms were viewed in Iran as a symbol of Russianness. Nasir al-Din, who was widely regarded as a deeply superficial and shallow man, was not interested in having his Cossack Brigade be an effective military force, and for him merely seeing his brigade ride before him while dressed in their brightly colored uniforms was quite enough.
Sources: en.wikipedia.org
== History == Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. As of 2015, setipiprant is currently under development by Allergan for the prevention of androgenic alopecia after their successful acquisition of Kythera.
Uterine prolapse occurs when there is a disruption to any of the structures mentioned above that help hold the uterus in place. Weakening of the levator ani muscles can occur during vaginal childbirth, in which portions of the muscle can detach from the bony pelvis, or through age-related changes to musculature, and this can lead to a loss of support for the uterus. Pregnancy, vaginal childbirth, or injury can also stretch and weaken the uterosacral ligaments, leading to poor suspension or positioning of the uterus so that it is no longer supported by pelvic floor muscles. Problems with the vaginal wall, such as trauma or loss of smooth muscle support in the wall, can lead to the uterus collapsing downward due to a loss of support. When the uterus prolapses, it also drags the upper portion of the vagina (the apical vagina) along with it due to its anatomic relationship with the apical vagina. Additionally, the pelvic musculature and connective tissues are estrogen sensitive and respond to changes in estrogen level. Estrogen deficiency, which can occur during menopause, can affect the production of collagen that is needed to build connective tissue that makes up ligaments and fascia, which can contribute to uterine prolapse. This is also a reason that connective tissue disorders can predispose certain people to uterine prolapse.
On television, d'Abo played Ta'Ra, an alien medical officer in the science fiction miniseries Something Is Out There (1988), which was followed by a six-episode NBC mini-series of the same name, and she played Anne Summerton in the TV adaptation of Jeffrey Archer's novel Not a Penny More, Not a Penny Less (1990) directed by Clive Donner. D'Abo had a supporting role as a pretentious stained-glass artist in the low-budget British comedy Leon the Pig Farmer (1992). She appeared in the 1994 film The Browning Version and starred in Timelock (1996). D'Abo has had roles in various low-budget, straight-to-video action, horror and fantasy films such as Tomcat: Dangerous Desires (1992), as well as guest roles on television shows Tales from the Crypt (1993), Red Shoe Diaries (1992) and Murder, She Wrote (1992). She reunited with her James Bond director John Glen for a guest-starring role on the television series Space Precinct and for the feature film The Point Men (2001). Glen later said that he cast her in three different projects was because she was one of his favourite actresses. She played the mother of Lara (played by Keira Knightley) in the television miniseries version of Doctor Zhivago (2002), and she was Queen Hecuba in the Emmy-nominated miniseries Helen of Troy (2003). She had a small role in the French film L'Enfer (Hell, 2005), directed by Danis Tanovic whose stars included fellow Bond Girl Carole Bouquet. D'Abo and John Cork wrote the book Bond Girls Are Forever, published in 2002, which is a tribute to the women who have played the role of a Bond girl.
Sources: en.wikipedia.org
==== 1988 Seoul Olympics ==== A famous case of AAS use in a competition was Canadian Ben Johnson's victory in the 100 m at the 1988 Summer Olympics. He subsequently failed the drug test when stanozolol was found in his urine. He later admitted to using the steroid as well as Dianabol, testosterone, Furazabol, and human growth hormone amongst other things. Johnson was stripped of his gold medal as well as his world-record performance. Carl Lewis was then promoted one place to take the Olympic gold title. Lewis had also run under the current world record time and was therefore recognized as the new record holder. Johnson was not the only participant whose success was questioned: Lewis had tested positive at the Olympic Trials for pseudoephedrine, ephedrine and phenylpropanolamine. Lewis defended himself, claiming that he had accidentally consumed the banned substances. After the supplements that he had taken were analyzed to prove his claims, the USOC accepted his claim of inadvertent use, since a dietary supplement he ingested was found to contain "Ma huang", the Chinese name for Ephedra (ephedrine is known to help weight loss). Fellow Santa Monica Track Club teammates Joe DeLoach and Floyd Heard were also found to have the same banned stimulants in their systems, and were cleared to compete for the same reason. The highest level of the stimulants Lewis recorded was 6 ppm, which was regarded as a positive test in 1988.
== Biochemical function == β-Alanine residues are rare. It is a component of the peptides carnosine and anserine and also of pantothenic acid (vitamin B5), which itself is a component of coenzyme A. β-alanine is metabolized into acetic acid.
== Safety == As an oxidant, silver nitrate should be properly stored away from organic compounds. It reacts explosively with ethanol. Despite its common usage in extremely low concentrations to prevent gonorrhea and control nosebleeds, silver nitrate is still very toxic and corrosive. Brief exposure will not produce any immediate side effects other than the purple, brown or black stains on the skin, but upon constant exposure to high concentrations, side effects will be noticeable, which include burns. Long-term exposure may cause eye damage. Silver nitrate is known to be a skin and eye irritant. Silver nitrate has not been thoroughly investigated for potential carcinogenic effect.
Sources: en.wikipedia.org
The solvent depends on peptide sequence and application. Water or aqueous buffer works for many hydrophilic peptides, while hydrophobic peptides may require a water-miscible organic solvent. The chosen solvent must be compatible with the assay or analytical instrument.
No. Some material may remain as insoluble particles, adsorb to surfaces, or degrade during handling. Recovery can be checked by analytical methods such as chromatography or mass spectrometry.
Aliquoting limits repeated freezing and thawing, which can cause aggregation or loss. Single-use portions also reduce contamination risk. Storage conditions depend on peptide stability.
Most reconstituted peptide solutions are kept cold, often at 2–8 °C for short-term use. Longer storage may require freezing at -20 °C or below, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or degradation.